Literature DB >> 2956450

Indomethacin reduces proteinuria in passive Heymann nephritis in rats.

C Zoja, A Benigni, P Verroust, P Ronco, T Bertani, G Remuzzi.   

Abstract

Indomethacin has been used to lower proteinuria in human glomerular diseases with controversial results. The mechanism of indomethacin beneficial effects has not been established. A possible explanation is that indomethacin reduces proteinuria by inhibiting the synthesis of renal prostaglandins (PGs); however, appropriate studies to address this issue have never been done. The objectives of the present study were: to investigate whether indomethacin influences protein excretion in an experimental model of immunologically-mediated glomerular disease; to establish if the possible favorable effect of indomethacin on proteinuria is related to a reduction in glomerular filtration rate (GFR); to establish the possible association between the antiproteinuric effect of indomethacin and its inhibitory effect on arachidonic acid (AA) metabolites of renal or extrarenal origin; and to further investigate the relationship between proteinuria and renal thromboxane (Tx) synthesis previously demonstrated in experimental models of nephrotoxic nephritis and adriamycin (ADR) nephrosis. To this purpose we used an experimental immune-complex disease, passive Heymann nephritis (PHN) which was induced in the rat by a single intravenous (i.v.) injection of heterologous serum directed against a brush border component (gp 330 antigen). Indomethacin at a dose of 6 mg/kg intraperitoneally (i.p.) administered for four consecutive days to PHN animals during the period of heavy proteinuria, effectively reduced urinary protein excretion. The reduction in proteinuria does not appear to be a consequence of a reduction in GFR as documented by inulin clearance. Glomerular synthesis and urinary excretion of vasodilatory prostacyclin (PGI2) and PGE2 were decreased or unchanged in PHN animals in respect to control animals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2956450     DOI: 10.1038/ki.1987.147

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

2.  Experimental Models of Membranous Nephropathy.

Authors:  J Ashley Jefferson; Jeffrey W Pippin; Stuart J Shankland
Journal:  Drug Discov Today Dis Models       Date:  2010

3.  Heymann nephritis revisited--new insights into the pathogenesis of experimental membranous glomerulonephritis.

Authors:  E De Heer; J A Bruijn; P J Hoedemaeker
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

4.  Complement C5b-9 induces receptor tyrosine kinase transactivation in glomerular epithelial cells.

Authors:  A V Cybulsky; T Takano; J Papillon; A J McTavish
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

5.  Complement C5b-9-mediated arachidonic acid metabolism in glomerular epithelial cells : role of cyclooxygenase-1 and -2.

Authors:  T Takano; A V Cybulsky
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

6.  Cytosolic phospholipase A2-alpha associates with plasma membrane, endoplasmic reticulum and nuclear membrane in glomerular epithelial cells.

Authors:  J Liu; T Takano; J Papillon; A Khadir; A V Cybulsky
Journal:  Biochem J       Date:  2001-01-01       Impact factor: 3.857

7.  Leukotriene D4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis.

Authors:  T Katoh; E A Lianos; M Fukunaga; K Takahashi; K F Badr
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 8.  Prostaglandin inhibitors in the treatment of nephrotic syndrome.

Authors:  J M Bergstein
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714

Review 9.  Nonsteroidal Anti-Inflammatory Drugs and the Kidney.

Authors:  Walter H Hörl
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.